Browsing Tag
SAFEbody technology
1 post
First patient dosed in Adagene’s Phase 2 study of Muzastotug (ADG126) with KEYTRUDA for microsatellite stable colorectal cancer
Find out how Adagene’s Muzastotug and KEYTRUDA combination could redefine immunotherapy for microsatellite stable colorectal cancer.